How long does a peptide vial last? The math, with examples.

“How long will this vial last me?” is the most common purchasing question in peptide use. The answer depends on three things: the total content of the vial, the dose per administration, and the dosing frequency. This article walks through the math with examples, then explains why the answer matters less than most people think.

Math, not medical advice

Joust doesn’t recommend doses, prescribe protocols, or claim therapeutic benefits. The calculations below describe how to project vial duration from values you already have. Decisions about what to take and how often to take it are decisions you make with a qualified healthcare provider.

The simple version

Two formulas cover most cases.

Doses per vial = vial total mg ÷ dose per administration mg
Vial duration = doses per vial ÷ doses per week (in weeks)

A few worked examples.

A 10 mg vial with a 2.5 mg dose administered weekly contains 4 doses. The vial lasts 4 weeks.

A 10 mg vial with a 0.5 mg dose administered weekly contains 20 doses. The vial lasts 20 weeks on the dose math alone.

A 10 mg vial with a 2.5 mg dose administered twice weekly still contains 4 doses, but those doses are spread across 2 weeks. The vial lasts 2 weeks.

A 30 mg vial with a 5 mg dose administered weekly contains 6 doses and lasts 6 weeks.

This is the math people usually want. It is also incomplete. The dose math tells you how many doses are in the vial. It does not tell you whether the vial is still usable when you get to dose six.

Why the calculation is more nuanced

Bacteriostatic water has a 28-day window after first puncture. The benzyl alcohol preservative in the water is considered effective for up to 28 days, after which the bottle should be discarded regardless of the volume remaining. The reconstituted peptide also has its own stability window in solution, which may be shorter or longer than the water’s 28 days.

This creates a ceiling on vial duration that is independent of the dose math. A vial that would mathematically last 20 weeks at your dose only contains usable product for as long as the beyond-use date allows. If the BUD is 28 days, that 20-week supply collapses to 4 weeks of actual usable doses. The remainder is discarded.

Your effective vial duration is the shorter of:

The duration the dose math predicts
The duration the BUD allows

For most peptides on most dosing schedules, the BUD is the constraint, not the math. This is where careful planning at reconstitution time pays off.

Higher concentration doesn’t change the doses, only the draw volume

A common misconception is that reconstituting with less water somehow makes a vial last longer. It doesn’t. The total mg in the vial is fixed at the moment it’s filled by the pharmacy. Adding less water gives a higher concentration, which means a smaller draw volume per dose, but the mg per dose and the doses per vial are unchanged.

A 10 mg vial reconstituted with 2 mL gives 5 mg/mL. A 2.5 mg dose requires a 0.5 mL draw, which reads as 50 units on a U-100 syringe.

The same 10 mg vial reconstituted with 1 mL gives 10 mg/mL. The same 2.5 mg dose requires a 0.25 mL draw, which reads as 25 units on a U-100 syringe.

Both reconstitutions yield 4 doses. Both vials last 4 weeks at weekly dosing. The benefit of the higher concentration is operational: a 25-unit draw lands more reliably on whole-unit marks than fractional volumes. The benefit of the lower concentration is the inverse — small doses are easier to measure when the draw volume is larger.

The choice between high and low concentration is about syringe precision, not vial economy.

Worked example: tirzepatide titration

The label for tirzepatide (Mounjaro and Zepbound) specifies a titration schedule starting at 2.5 mg weekly and escalating to higher doses at intervals of at least 4 weeks. A user moving through 2.5 mg → 5 mg → 7.5 mg → 10 mg over 16 weeks consumes more total mg per week as they escalate, so vial duration changes with each step.

Worked at the dose math level:

A 30 mg vial at 2.5 mg weekly: 12 doses, 12 weeks
A 30 mg vial at 5 mg weekly: 6 doses, 6 weeks
A 30 mg vial at 7.5 mg weekly: 4 doses, 4 weeks
A 30 mg vial at 10 mg weekly: 3 doses, 3 weeks

But the BUD constraint applies on top of these numbers. If the reconstituted vial has a 28-day window, the 12-week supply at the starting dose is capped at 4 weeks. The remaining 8 weeks of mathematical doses are discarded.

There are two practical responses. Reconstitute only what you’ll use within the BUD window, by using a smaller initial vial size. Or reconstitute the full vial at a higher concentration to make every dose smaller in volume while still using all of it within the window. The second option only works if the dose math says you can use the vial within the BUD.

For a starting-dose user with a 30 mg vial, the math says they can’t use the full vial in 28 days even at a moderate escalation pace. Ordering a smaller vial — or accepting waste — are the available options. Planning around titration steps matters for purchasing.

The supply planning problem

For a long-term protocol, vial-by-vial thinking is inadequate. You need a 2 to 3 month horizon that accounts for:

Projected dose consumption across titration steps
Lead time from your pharmacy from order to delivery
Remaining BUD on any vial currently in use
Buffer for missed deliveries or unexpected demand

Joust automates this calculation. The math works the same way you do it manually — projected consumption against remaining BUD against pharmacy lead time — but the app keeps the dates current as you log doses.

When the math gets complicated

Real protocols rarely follow the simple “vial total ÷ dose” formula cleanly. Complications include:

Variable dosing schedules. Titration steps, planned cycles, and seasonal breaks all shift consumption rates.
Combination protocols. Multiple peptides on different schedules each have their own BUD and reorder timing.
Real-world adherence. Skipped doses, accidental double-doses, and prescriber-directed adjustments all deviate from the planned consumption rate.
Vial size changes. Switching from a 10 mg to a 30 mg vial changes the BUD economics dramatically.

The simple math breaks down quickly with these. This is the operational complexity that motivated Joust’s tracking design: the inventory math has to account for both consumption and decay, in real time, with whatever dosing variations actually happen.

Practical guidance

Before reconstituting:

Calculate vial duration based on your prescribed dose
If the math says the vial will last more than 28 days, either order smaller vials, reconstitute at a higher concentration that still fits your dose precision, or accept that some product will be discarded
Note the lead time from your pharmacy and plan reorders 1 to 2 weeks before your projected vial empty date
Track actual consumption, not theoretical, because real-world doses drift from the plan

After reconstitution:

Mark the reconstitution date and the BUD on the vial physically
Set a reminder for the BUD date
Reorder before the current vial runs out, accounting for pharmacy lead time

When to talk to a healthcare provider

Talk to your prescriber if:

You’re considering changing your reconstitution practice in a way that affects dose precision
You consistently have product remaining at the BUD that you discard
Your titration schedule has changed and your purchasing pattern hasn’t caught up
You experience supply gaps that lead to missed doses

Supply planning sounds operational, but it has clinical consequences. Missed doses, dose interruptions, and inconsistent timing all affect protocol outcomes. Your prescriber’s input on the practical side of supply matters.